Extranodal presentation in limited-stage diffuse large Bcell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001
AuthorsStephens, Deborah M
Constine, Louis S
Fitzgerald, Thomas J
Leonard, John P
Kahl, Brad S
Song, Joo Y
LeBlanc, Michael L
Smith, Sonali M
Persky, Daniel O
Friedberg, Jonathan W
UMass Chan AffiliationsRadiation Oncology
Document TypeLetter to the Editor
MetadataShow full item record
AbstractSeveral recent trials have changed the standard-of-care for patients with limited stage (LS) diffuse large B-cell lymphoma (DLBCL) by minimizing the number of chemoimmunotherapy cycles and/or eliminating the need for radiotherapy without compromising long-term outcomes. However, there may be patient subsets where an abbreviated-treatment approach is insufficient. With this in mind, Bobillo et al., retrospectively reviewed LS DLBCL patients treated at a single institution with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) for four to six cycles with or without radio-therapy. This group reported that an extranodal presentation had shorter progression-free (PFS) and overall survival (OS) compared with nodal presentation. In these patients, consolidative radiotherapy prolonged survival in patients with extranodal disease, especially those with a positive positron emission tomography (PET) scan at the end of chemoimmunotherapy. In response, we analyzed similar patients treated on three consecutive SWOG studies (S0014, S0313, S1001; clinicaltrails gov. Identifier: NCT00005089, NCT00070018, NCT01359592).
SourceStephens DM, Li H, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, Song JY, LeBlanc ML, Smith SM, Persky DO, Friedberg JW. Extranodal presentation in limited-stage diffuse large Bcell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001. Haematologica. 2022 Nov 1;107(11):2732-2736. doi: 10.3324/haematol.2022.281004. PMID: 35833300; PMCID: PMC9614528.
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/51355
RightsCopyright (c) 2022 Ferrata Storti Foundation. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Except where otherwise noted, this item's license is described as Copyright (c) 2022 Ferrata Storti Foundation. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.